

RESUME

Bojian Zheng (鄭伯建)

**Department of Microbiology, the University of Hong Kong,
University Pathology Building, Queen Mary Hospital Compound, Hong Kong
Tel: (852)-2855-4383 Fax: (852)-2855-1241 E-mail: bzheng@hkucc.hku.hk**

Research field:

1. Viral Emerging Infectious Diseases-Epidemiology, Immunology and Anti-viral Therapy (SARS, H5N1)
2. Immunotherapy for Chronic Viral Infections and Related Cancers (HBV, HIV, EBV related NPC)

Education:

Ph.D (1986 – 1990) Microbiology, University of Hong Kong, Hong Kong.
M.S (1983 – 1985) Microbiology and Immunology, Sun Yat Sen University of Medical Sciences, Guangzhou.
M.D (1977 – 1982) Guangzhou Medical College, Guangzhou.

Professional Appointments:

Professor (2008 –) Department of Microbiology, The University of
Associate Professor (2003–2008) Hong Kong, Hong Kong
Assistant Professor (2002–2003) .
Lecturer (1997-2002)
Scientist (1996 – 1997) LifeTech Corporation. Toronto, Ontario, Canada.
Research Associate (1993–1996) Department of Biology, McMaster University.
Postdoctoral Fellow (1990–1993) Hamilton, Ontario, Canada.
Distinguish Professor (2009-) Guangzhou Medical College, China.

Guest Professor (2006–)	Beijing Institute of Microbiology & Epidemiology, China
Consultant Professor (2006–)	Tsinghua University, China.
Guest Professor (2004–)	Beijing University, China.
Senior Consultant (2003–)	Shenzhen CDC, China.
Consultant (2003–)	Guangzhou CDC, China.

Editorial Board Member of Journals

The World Journal of Gastroenterology

Journal of Microbes and Infection

Research grants (Total = about HK\$ 37 million or USD 4.6 million)

1. Co-administration of antiviral and anti-inflammatory agents against avian influenza H5N1 infection in animal model
Principal Investigator (HKU project No. 21009975 and RFCID ref. No. 09080762)
RFCID: HK\$0.8 million (2010-2011)
2. Cross-protective efficacy of immunization with different forms of M2 vaccines and their combination with HA vaccines against highly pathogenic H5N1 influenza A virus in mice
Principal Investigator (HKU project No. 21009964 and RFCID ref. No. 09080812)
RFCID: HK\$0.8 million (2009-2011)
3. A feasibility study on the inhibition of swine influenza A virus H1N1 infection using siRNAs with a unique motif
Principal Investigator (HKU project No. 21009976 and RFCID ref. No. Commissioned-study)
RFCID: HK\$0.8 million (2009-2011)
4. The Role of Complement Activation in Severe Pneumonia Caused by Avian Influenza Virus H5N1 Infection
Principal Investigator (HKU project No.10208608 and RGC No. HKU781608M)
RGC: HK\$0.55 million (2008-2009)
5. Control of Pandemic and Inter-pandemic Influenza

- Sub-project: Study of AAV- and peptide-based vaccines against avian influenza virus H5N1 infection in animal model
Principal Investigator (HKU project No. 10208078 and UGC No. AoE/M-12/06)
AoE/UGC: HK\$0.54 million (2008-2010)
6. SARS-CoV S Protein Receptor-binding Domain-based Vaccines
Co-Principal Investigator (HKU project No. 21005328 and NIH grant No. R01 AI068002)
NIH: US\$120,000 (subproject 2007-2011)
 7. A feasibility study of human T cell epitope-based vaccines against H5N1 avian influenza virus
Principal Investigator (HKU project No. 10208033 and RGC Project. No. F-HK40/07T)
RGC/CGF: HK\$0.03 million (2007-2008)
 8. A novel anti-H5N1 avian influenza virus agent using silver nanoparticle
Principal Investigator (HKU project No. 21009278 and ITF ref. No. GHP/008/06)
ITF: HK\$ 5.5 million (2007-2009)
 9. Study of AAV- and peptide-based vaccine candidates against avian influenza virus H5N1 infection in animal model
Principal Investigator (HKU project No. 21009486 and RFCID ref. No. 07060582)
RFCID: HK\$0.8 million (2007-2009)
 10. Study of vaccine HA-M2 against H5N1 avian influenza virus
Co-Investigator (HKU project No.10207629)
Matching fund for 863 from HKU: HK\$ 0.35 million
863: RMB 1 million (2007-2008)
 11. A pilot study for development of anti-influenza A compounds
Principal Investigator (HKU project No. 21009487 and RFCID ref. No. 07060432)
RFCID: HK\$0.08 million (2007-2008)
 12. A feasibility study on the inhibition of avian influenza virus H5N1 replication using siRNA
Principal Investigator (HKU project No. 10207060 and RGC ref. No. HKU 7546/06M)

- RGC: HK\$ 0.98 million (2007-2009)
13. A longitudinal study of HIV-1 drug-resistance for improving management of patients on HAART
Principal Investigator (HKU project No. 21004713 and ATF ref. No. MSS140)
Council for the AIDS Trust Fund: HK\$ 2.65 million (2006-2009)
 14. A preliminary study on the inhibition of avian influenza virus H5N1 replication using siRNA
Principal Investigator (HKU project No. 10206833)
CRGC: HK\$ 0.08 million (2006)
 15. Evaluation of antiviral pathophysiology in HIV patients on HAART by monitoring the progression from persistent to latent infection
Principal Investigator (HKU project No. 21004418 or ATF ref. No. MSS 129)
Council for the AIDS Trust Fund: HK\$ 2.38 million (2005-2008)
 16. Studies of SARS virus vaccines
Principal Investigator (HKU project No. 21009592 or RFCID Project no. 01030292)
RFCID: HK\$0.805 million (2005-2007)
 17. A mechanism study of spike protein in the infection of SARS coronavirus
Principal Investigator (HKU project No. 10206439)
CRGC: HK\$ 0.03 million (2005-2006)
 18. Development of new technique for detection of HIV specific cytotoxic T lymphocytes
Principal Investigator (HKU project No. 21004112 or ATF ref. No. MSS111)
Council for the AIDS Trust Fund: HK\$ 0.65 million (2004-2005)
 19. Ex vivo expansion and functional study of CD4 T cells
Principal Investigator (HKU project No. 21004113 or ATF ref. No. MSS112)
Council for the AIDS Trust Fund: HK\$ 0.63 million (2004-2005)
 20. Functional studies on prevalent CCR5 mutants in Hong Kong
Principal Investigator (HKU project No. 21004124 or ATF ref. No. MSS108)
Council for the AIDS Trust Fund: HK\$ 0.59 million (2004-2005)
 21. Polymorphism of CCR5 promoter gene in Chinese and its effects on HIV disease progression

- Principal Investigator (HKU project No. 21004125 or ATF ref. No. MSS109)
Council for the AIDS Trust Fund: HK\$ 0.55 million (2004-2005)
22. Studies of SARS virus vaccines
Principal Investigator (HKU project No. 10205278)
CRGC: HK\$ 0.06 million (2004-2005)
 23. A study of SARS virus animal vaccines
Principal Investigator (HKU project No. 10205653)
CRGC: HK\$ 0.03 million (2004-2005)
 24. Immune and biological therapies for hepatitis B virus infection
Principal Investigator (HKU project No. 00503758)
UDF: HK\$2.5 million (2003-2007)
 25. A study of antiviral peptides targeting spike and matrix proteins of SARS coronavirus
Principal Investigator (HKU project No. 10204786 or RGC ref. No. HKU 7551/03M)
RGC/SARS: HK\$0.65 million (2003-2004)
 26. Primary study for development of an inactivated coronavirus vaccine
Principal Investigator (HKU project No. 21395063)
HKU SARS Research Fund: HK\$0.10 million (2003-2004)
 27. A study of dendritic cell-based vaccine for immune therapy of chronic hepatitis B virus infection
Principal Investigator (HKU project No. 10204871)
CRGC: HK\$ 0.03 million (2003-2004)
 28. The study of Anti-SARS virus siRNA in cell culture
Principal Investigator (HKU project No. 26003993)
Donation: HK\$ 0.31 million (2003-)
 29. Development of oral DNA vaccine for immune therapy of chronic HBV infection
Principal Investigator (HKU project No. 10204517)
CRGC: HK\$ 0.12 million (2002-2003)
 30. The Epidemiology of CXCR4 and SDF-1 Polymorphism in Chinese HIV Patients and Healthy People

- Principal Investigator (HKU project No. 21003616 or ATF ref. No. MSS 093)
Council for the AIDS Trust Fund: HK\$ 2.3 million (2002-2005)
31. CXCR4 expression on CD4+ T cells in HIV infection
Principal Investigator (HKU project No. 21003617 or ATF ref. No. MSS 094)
Council for the AIDS Trust Fund: HK\$ 1.2 million (2002-2004)
32. Establishment of core facilities for the HKU HIV/AIDS research laboratories
Co-Principal Investigator (HKU project No. 21003483)
Council for the AIDS Trust Fund: HK\$ 8 million (2002-2003)
33. Immune response in HIV patients on traditional Chinese medicine treatment
Principal Investigator (HKU project No. 26003602)
Donation: HK\$ 0.684 million (2002-)
34. Functional studies of dendritic cells in chronic Chinese hepatitis B patients
Principal Investigator (HKU project No. 10203941 or RGC ref. No. N_HKU712/01)
NSFC/RGC: HK\$ 0.7 million (2001-2004)
35. CCR5 expression on antigen-presenting cells in HIV infection
Principal Investigator (HKU project No. 21003357 or ATF ref. No. MSS 072)
Council for the AIDS Trust Fund: HK\$ 1.447 million (2001-2004)
36. The pattern of chemokine receptor polymorphism in healthy and HIV positive Chinese adults
Co-Principal Investigator (HKU project No. 21003358 or ATF ref. No. MSS 071)
Council for the AIDS Trust Fund: HK\$ 0.999 million (2001-2003)
37. A study of $\gamma\delta$ T cell response to nasopharyngeal carcinoma
Principal Investigator (HKU project No. 10203624 or RGC ref. No. HKU 7282/01M)
RGC: HK\$ 0.7 million (2001-2003)
38. A study of novel approach of therapeutic vaccine for HBV chronic infection in transgenic mouse model
Principal Investigator (HKU project No. 10203360)
CRGC: HK\$ 0.04 million (2000-2002)
39. A detailed analysis of cytotoxic T lymphocytes immune surveillance against nasopharyngeal carcinoma

Principal Investigator (HKU project No. 10201830 & 10202157)

CRGC: HK\$ 0.14 million (1997-1999)

Publications

Journals papers published: (IF=Impact Factor in 2009 issue; Citations in SCI 2010 issue)

Total citations = 2,984 H-index = 26

1. Lau SK, Poon RW, Wong BH, Wang M, Huang Y, Xu H, Guo R, Li KS, Gao K, Chan KH, **Zheng BJ**, Woo PC, Yuen KY. Co-existence of different genotypes in the same bat and serological characterization of Rousettus bat coronavirus HKU9 belonging to a novel Betacoronavirus subgroup. *J Virol*. In press. 2010. (IF = 5.150)
2. Zhao G, Lin Y, Du L, Guan J, He Y, Sun S, Xiao W, Chen M, Chan CCS, Kou Z, Lustigman S, Jiang S, **Zheng BJ***, Zhou Y*. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. *Vaccine* In press. 2010. * **Corresponding author**. (IF = 3.616)
3. **Zheng B**, Chan KH, Zhang AJX, Zhou J, Chan CCS, Poon VKM, Zhang K, Leung CHV, Jin DY, Woo PCY, Chan JFW, To KKW, Chen H, Yuen KY. D225G mutation in haemagglutinin of pandemic Influenza H1N1 (2009) virus enhances virulence in mice. *Exp Biol Med*. 235(8):981-8. Aug. 2010. (IF = 2.635)
4. Lau SK, Woo PC, Wong BH, Wong AY, Tsoi HW, Wang M, Lee P, Xu H, Poon RW, Guo R, Li KS, Chan KH, **Zheng BJ**, Yuen KY. Identification and complete genome analysis of three novel paramyxoviruses, Tuhoko virus 1, 2 and 3, in fruit bats from China. *Virology* 404(1):106-16. Aug. 2010. (IF = 3.042)
5. Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, **Zheng BJ**, Zhou Y. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. *Virol J* 7(1):151. Jul. 2010. (IF = 2.435)
6. Du L, Zhao G, Zhang X, Liu Z, Yu H, **Zheng BJ**, Zhou Y, Jiang S. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-

- specific neutralizing monoclonal antibodies. *Biochem Biophys Res Commun* 397(3):580-585. Jul 2010. (IF = 2.548)
7. Tang BSF, Chan JFW, Chen M, Tsang OTY, Mok MY, Lai RWM, Lee R, Que TL, Tse H, Li IWS, To KKW, Cheng VCC, Chan EYT, **Zheng B**, Yuen KY. Disseminated penicilliosis, recurrent bacteremic non-typhoidal salmonellosis and burkholderiosis associated with acquired immunodeficiency due to autoantibody against interferon gamma. *Clin Vaccine Immunol*. 17(7):1132-1138. Jul. 2010. (IF = 2.373)
 8. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, **Zheng BJ**, Sun J, Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY. Identification of influenza A nucleoprotein as an antiviral target. *Nat Biotech*. 28(6):600-605. Jun 2010. (IF = 29.495)
 9. Du L, Zhao G, Chan CCS, Li L, He Y, Zhou Y, **Zheng BJ**, Jiang S. A 219-mer CHO-expressing RBD of SARS-CoV S protein induces potent immune responses and protective immunity. *Viral Immunol*. 23(2):211-219. Apr. 2010. (IF = 1.949)
 10. Yang M, Sun L, Wang S, Ko KH, Xu H, **Zheng BJ**, Cao X, Lu L. Novel Function of B Cell-Activating Factor in the Induction of IL-10-Producing Regulatory B Cells. *J Immunol*. 184: 3321-3325. Apr. 2010. (IF = 5.646)
 11. Li Y, Zhao JK, Wang M, Han ZG, Cai WP, **Zheng BJ**, Xu HF. Current antibody-based immunoassay algorithm failed to confirm three late-stage AIDS cases in China: case report. *Virol J*. 7(1):58. Mar. 2010. (IF = 2.435)
 12. Lau SK, Li KS, Huang Y, Shek CT, Tse H, Wang M, Choi GK, Xu H, Lam CS, Guo R, Chan KH, **Zheng BJ**, Woo PC, Yuen KY. Eco-epidemiology and complete genome comparison of SARS-related Rhinolophus bat coronavirus in China reveal bats as reservoir for acute, self-limiting infection that allows recombination events. *J Virol*. 84(6):2808-2819. Mar. 2010. (IF = 5.150)
 13. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, Liu R, Ho KY, Chu KH, Watt CL, Luk WK, Lai KY, Chow FL, Mok T, Buckley T, Chan JF, Wong SS, **Zheng B**, Chen H, Lau CC, Tse H, Cheng VC, Chan KH, Yuen KY. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic

- H1N1 2009 influenza virus infection. *Clin Infect Dis*. 50(6):850-9. Mar. 2010. (IF = 8.195, Citations = 6)
14. Chen DQ, Zeng Y, Zhou J, Yang L, Jiang S, Huang JD, Lu L, **Zheng BJ***. Association of candidate susceptible loci with chronic infection with hepatitis B virus in a Chinese population. *J Med Virol*. 82(3):371-378. Mar. 2010. * **Corresponding author**. (IF = 2.470 Citations = 6)
 15. Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, **Zheng BJ***, Zhou Y*. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. *Virology*. 7(1):9. Jan. 2010. * **Corresponding author**. (IF = 2.435)
 16. Li IW, Chan KH, To KW, Wong SS, Ho PL, Lau SK, Woo PC, Tsoi HW, Chan JF, Cheng VC, **Zheng BJ**, Chen H, Yuen KY. Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses. *J Clin Virol*. 46(4):325-30. Dec. 2009. (IF = 3.124, Citations = 3)
 17. Lo CKC, Lam QLK, Yang M, Ko KH, Sun L, Ma R, Wang S, Xu H, Tam S, Wu CY, **Zheng BJ**, Lu L. Leptin Signaling Protects NK Cells from Apoptosis During Development in Mouse Bone Marrow. *Cellular & Molecular Immunology* 6(5):353-360. Oct. 2009. (IF = 2.765)
 18. Du L, Zhao G, Chan CCS, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, **Zheng BJ**, Jiang S. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. *Virology* 393:144-150. Oct. 2009. (IF = 3.042, Citations = 1).
 19. Siu KL, Chan CP, Chan C, **Zheng BJ**, Jin DY. Severe acute respiratory syndrome coronavirus nucleocapsid protein does not modulate transcription of human *FGL2* gene. *J Gen Virol*. 90:2107-2113. Sep 2009. (IF = 3.260, Citations = 1)
 20. Zhou J, Huang JD, Poon VKM, Chen DQ, Chan CCS, Ng F, Guan XY, Watt RM, Lu L, Yuen KY, **Zheng BJ***. Functional dissection of an IFN- α/β receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection. *J*

- Hepat.* 51(2):322-332. August 2009 * **Corresponding author.** (IF = 7.818, Citations = 1)
21. Chen M, Huang JD, Hu L, **Zheng BJ**, Chen L, Tsang SL, Guan XY. Transgenic CHD1L expression in mouse induces spontaneous tumors. *Plos One.* 4(8):e6727. 24 August 2009. (IF = 4.351)
 22. Chen LL, Hu L, Chan HM, Tsao SW, Xie D, Huo KK, Fu L, Ma S, **Zheng BJ**, Guan XY. Chromodomain Helicase/ATPase DNA Binding Protein 1-Like (CHD1L) Suppresses the Nucleus-to-Mitochondria Translocation of Nur77 to Sustain Hepatocellular Carcinoma Cell Survival. *Hepatology* 50(1):122-129. July 2009. (IF = 10.840, Citations = 1)
 23. Du L, Zhao G, Li L, He Y, Zhou Y, **Zheng BJ**, Jiang S. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. *Biochem Biophys Res Commun* 384(4):486-90. July 10, 2009. (IF = 2.548, Citations = 2)
 24. Zhang HJ, Wang YX, Wu H, Jin DY, Wen YM, **Zheng BJ***. The Y271 and I274 Amino Acids in Reverse Transcriptase of Human Immunodeficiency Virus-1 Are Critical to Protein Stability. *PLoS One.* 4(7):e6108. July 3, 2009 * **Corresponding author.** (IF = 4.351)
 25. Wang M, Fu CX, **Zheng BJ**. Antibodies against H5 and H9 Avian Influenza among Poultry Workers in China. *N Engl J Med.* 360(24):2583-84. June 11, 2009 (IF = 47.050, Citations = 3)
 26. Siu KL, Kok KH, Ng MH, Poon VK, Yuen KY, **Zheng BJ**, Jin DY. Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3-TANK-TBK1/IKKepsilon complex. *J Biol Chem.* 284(24):16202-9. June 12, 2009. (IF = 5.328, Citations = 4)
 27. Zhou J, Chen DQ, Poon VKM, Zeng Y, Ng F, Lu L, Huang JD, Yuen KY, **Zheng BJ***. A regulatory polymorphism in interferon- γ receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. *Immunogenetics.* 61(6):423-430. June 2009. * **Corresponding author.** (IF = 2.988, Citation = 1)
 28. Xu K*, **Zheng BJ***, Zeng R*, Lu W, Lin YP, Xue L, Li L, Yang LL, Xu C, Dai J, Wang F, Li Q, Dong QX, Yang RF, Wu JR, Sun B. Severe Acute Respiratory

- Syndrome Coronavirus Accessory Protein 9b Is a Virion-Associated Protein. *Virology* 388(2):279-85. June 2009. (IF = 3.042, Citation = 1). * **Equal first-authors**
29. He ML, **Zheng BJ**, Chen Y, Wong KL, Huang JD, Lin MC, Yuen KY, Sung JJ, Kung HF. Development of interfering RNA agents to inhibit SARS-associated coronavirus infection and replication. *Hong Kong Med J*. 3 (Suppl 4):28-31. June 2009.
 30. Zhao XY, Li RS, Huang JQ, Chen ZW, **Zheng BJ**. A transcriptional study of SDF-1alpha expression in PBL and the correlation between SDF-1alpha transcription and HIV-1 infection. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi*. 23(3):204-7. June 2009.
 31. Sui HY, Zhao GY, Huang JD, Jin DY, Yuen KY, **Zheng BJ***. Small Interfering RNA Targeting M2 Gene Induces Effective and Long term Inhibition of Influenza A Virus Replication. *PloS One*. 4(5): e5671. May 22. 2009 * **Corresponding author**. (IF = 4.351, Citations = 3)
 32. Chan CM, Tse H, Wong SS, Woo PC, Lau SK, Chen L, **Zheng BJ**, Huang JD, Yuen KY. Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus. *J Clin Virol*. 45(1):54-60. May, 2009. (IF = 3.124)
 33. Du L, He Y, Zhou Y, Liu S, **Zheng BJ**, Jiang S. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. *Nat Rev Micro*. 7(3):226-236. March, 2009. (IF = 17.644, Citations = 7)
 34. Chen JY, Chen WN, Poon KMV, **Zheng BJ**, Lin X, Wang YX, Wen YM. Interaction between SARS-CoV helicase and a multifunctional cellular protein (Ddx5) revealed by yeast and mammalian cell two-hybrid systems. *Archives of Virology* 154(3):507-512. March, 2009. (IF = 1.909)
 35. Zhang Q, Su X, Seto D, **Zheng BJ**, Tian X, Sheng H, Li H, Wang Y, Zhou R. Construction and characterization of a replication-competent human adenovirus type 3-based vector for use as a live-vaccine candidate, and as a gene therapy vector. *Vaccine* 27(8):1145-53. Feb 18; 2009. (IF = 3.616, Citations = 4)

36. Jin DY, **Zheng BJ**. Roles of spike protein in the pathogenesis of SARS coronavirus. *Hong Kong Med J*. Suppl 2:37-40. Feb. 2009.
37. Chan CM, Lau SKP, Woo PCY, Tse H, **Zheng BJ**, Chen L, Huang JD, Yuen KY. Identification of Major Histocompatibility Antigen Class I C as an attachment coreceptor that facilitates Coronavirus HKU1 Spike-mediated infection. *J Virol*. 83(2):1026-1035. Jan. 2009. (IF = 5.150)
38. Zhou J, Smith DK, Lu L, Poon VKM, Ng F, Chen DQ, Huang JD, Yuen KY, Cao KY, **Zheng BJ***. A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection. *J Viral Hepat*. 16(1):45-52. Jan 2009. ***Corresponding author**. (IF = 3.348, Citations = 2)
39. Li Z, He ML, Yao H, Dong QM, Chen YC, Chan CY, **Zheng BJ**, Yuen KY, Peng Y, Sun Q, Yang X, Lin MC, Sung JJ, Kung HF. Inhibition of HBV replication and gene expression in vitro and in vivo with a single AAV vector delivering two shRNA molecules. *BMB Rep*. 42(1):59-64. Jan 31 2009. (IF = 2.276, Citations = 1)
40. Bian C, Zhang X, Cai X, Zhang L, Chen Z, Zha Y, Xu Y, Xu K, Lu W, Yan L, Yuan J, Feng J, Hao P, Wang Q, Zhao G, Liu G, Zhu X, Shen H, **Zheng B**, Shen B, Sun B. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. *Virology* 383(1):39-46. Jan 5, 2009. (IF = 3.042, Citations = 1).
41. Wang YX, Zhang HJ, Xu J, **Zheng BJ**, Wen YM. Mutational analysis of the “turn” of helix clamp motif of HIV-1 reverse transcriptase. *Biochem. Biophys. Res. Commun*. 377(3):915-920. Dec 19, 2008. (IF = 2.548, Citations = 1)
42. Chan CM, Woo PC, Lau SK, Tse H, Chen HL, Li F, **Zheng BJ**, Chen L, Huang JD, Yuen KY. Spike protein, S, of human coronavirus HKU1: role in viral life cycle and application in antibody detection. *Exp Biol Med* (Maywood). 233 (12):1527-1536. Dec 2008. (IF = 2.635, Citations = 1)
43. Lu CY, Lu JH, Chen WQ, Jiang LF, Tan BY, Ling WH, **Zheng BJ**, Sui HY. Potential infections of H5N1 and H9N2 avian influenza do exist in Guangdong populations of China. *Chinese Medical Journal*. 121(20):2050-2053. Oct. 2008. (IF = 0.952, Citations = 4)

44. Lo CKC, Lam QLK, Sun L, Wang S, Ko KH, Xu H, Wu CY, **Zheng BJ**, Lu L. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. *Arthritis and Rheumatism* 58(9):2700-2711. Sep 2008. (IF = 7.332, Citations = 3)
45. Lam QLK, Ko OKH, **Zheng BJ**, Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. *Proc Natl Acad Sci USA*. 105(39):14993-14998. Sep 30 2008. (IF = 9.432, , Citations = 13)
46. Lau SKP, Woo PCY, Tse H, Fu CTY, Au WK, Chen XC, Tsoi HW, Tsang THF, Chan JSY, Tsang DNC, Li SM, Tse CWS, Ng TK, Tsang OTY, **Zheng BJ**, Tam SCF, Chan KH, Zhou B, Yuen KY. Identification of novel porcine and bovine parvoviruses closely related to human parvovirus 4. *J Gen Virol*. 89(8): 1840-1848. Aug. 2008. (IF = 3.260, Citations = 8)
47. **Zheng BJ***, Du L, Zhao GY, Lin YP, Sui HY, Chan C, Ma S, Guan Y, Yuen KY. Studies of SARS virus vaccines. *Hong Kong Med J* 14(4, Suppl 4):39-43. Aug. 2008. * **Corresponding author**.
48. Huang JD, **Zheng BJ**, Sun HZ. Helicases as antiviral drug targets. *Hong Kong Med J* 14(4, Suppl 4):36-38. Aug. 2008.
49. Ma S, Chan KW, Lee T, Tang KH, Wo J, **Zheng BJ**, Guan XY. Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations. *Mol Cancer Res*. 6(7): 1146-1153. Jul. 2008. (IF = 4.162, Citations = 24)
50. **Zheng BJ**, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, Chen HL, Wong SSY, Lau SKP, Woo PCY, Chan KH, Jin DY, Yuen KY. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. *Proc Natl Acad Sci USA*. 105(23):8091-8096. June 10, 2008. (IF = 9.432; Citations = 27)
51. Li Z, Yao H, Ma Y, Dong Q, Chen Y, Peng Y, **Zheng BJ**, Huang JD, Chan CY, Lin MC, Sung JJ, Yuen KY, Kung HF, He ML. Inhibition of HBV gene expression and replication by stably expressed interferon- α 1 via adeno-associated viral vectors. *J Gene Med*. 10(6):619-627. June 2008. (IF = 2.968; Citations = 1)

52. Ma S, Lee TK, **Zheng BJ**, Chan KW, Guan XY. CD133(+) HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. *Oncogene*. 27:1749-1758. March 2008. (IF = 7.135; Citations = 64)
53. Du L, Zhao G, Lin Y, Chan CCS, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, **Zheng BJ***. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. *Vaccine* 26(13):1644-1651. March 20 2008. * **Corresponding author**. (IF = 3.616, Citations = 11)
54. Ma NF, Hu L, Fung JM, , Xie D, **Zheng BJ**, Chen L, Tang DJ, Fu L, Wu Z, Chen M, Fang Y, Guan XY. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. *Hepatology* 47(2):503-10. February 2008. (IF = 10.840; Citations = 10)
55. Du L, Zhao GY, Lin YP, Sui HY, Chan CC, Ma S, He YX, Jiang SB, Wu CY, Yuen KY, Jin DY, Zhou YS, **Zheng BJ***. Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection. *J Immunol*. 180(2): 948-956. January 15 2008. * **Corresponding author**. (IF = 5.646; Citations = 14)
56. Du L, Jian S, **Zheng BJ**. Development of subunit vaccines against severe acute respiratory symptom. *Drugs of Today*. 44(1):63-73. January 2008. (IF = 1.588, Citations = 1)
57. Yang N, Tanner J, Huang JD, **Zheng BJ**, Zhu N, Sun HZ. Inhibition of SARS coronavirus helicase by bismuth complexes. *Chem Commun*. (42):4413-5. Nov 14, 2007. (IF = 5.504; Citations = 7)
58. Chen Y, Chan VSF, **Zheng B**, Chan KYK, Xu X, To LYF, Huang FP, Khoo US, Lin CL. A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. *J Exp. Med*. 204:2529-2536. Oct 2007. (IF = 14.505; Citations = 5)

59. Lau SKP, Woo PCY, Li KSM, Huang Y, Wang M, Lam CSF, Xu H, Guo R, Chan KH, **Zheng BJ**, Yuen KY. Complete genome sequence of bat coronavirus HKU2 from Chinese horseshoe bats revealed a much smaller spike gene with a different evolutionary lineage from the rest of the genome. *Virology*. 367(2):428-439. Oct. 25, 2007. (IF = 3.042; Citations = 9)
60. Cao KY, Mao XP, Wang DH, Xiao N, Xu L, Yuan GQ, Dai SQ, **Zheng BJ**, Qiu SP. High Expression of PSM-E Correlated with Tumor Grade in Prostate Cancer: A New Alternatively Spliced Variant of Prostate-Specific Membrane Antigen. *Prostate*. 67(16):1791-1800. Oct 10, 2007. (IF = 3.081; Citations = 4)
61. Lam QL, **Zheng BJ**, Jin DY, Cao XT, Lu L. Leptin induces CD40 expression through the activation of AKT in murine dendritic cells. *J Biol. Chem.* 282(38):27587-97. Sep 21, 2007. (IF = 5.328; Citations = 10)
62. Du L, Kao RY, Zhou Y, He Y, Zhao G, Wong C, Jiang S, Yuen KY, Jin DY, **Zheng BJ***. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. *Biochem. Biophys. Res. Commun.* 359(1):174-9. July 20; 2007. * **Corresponding author**. (IF = 2.548; Citations = 15)
63. Yang N*, Tanner JA*, **Zheng BJ***, Watt RM, He ML, Lu LY, Jiang JQ, Shum KT, Lin YP, Wong KL, Lin MCM, Kung HF, Sun HZ, Huang JD. Bismuth Complexes Inhibit the SARS Coronavirus. *Angew Chem Int Edit.* 46(34):6464-6468. July 23; 2007. * **Equal first-authors**. (IF = 11.829; Citations = 6)
64. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, **Zheng BJ**, Guan XY. Identification and Characterization of Tumorigenic Liver Cancer Stem Cells. *Gastroenterology*. 132:2542–2556. June 2007. (IF = 12.899; Citations = 118)
65. Chen JH, Wong KH, Chan K, Lam HY, Lee SS, Li P, Lee MP, Tsang DN, **Zheng BJ**, Yuen KY, Yam WC. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. *J Clin Virol.* 39(2):125-31. June; 2007. (IF = 3.124; Citations = 5)
66. Chen DQ, **Zheng BJ***. Effects of PD-1 and PD-L1 in chronic viral infections. *J Micro Infect.* 2(2):118-119. Jun 2007. * **Corresponding author**.
67. Yuen MF, Wong DKH, **Zheng BJ**, Chan CCS, Yuen JCH, Wong BCY, Lai CL. Difference in T helper responses during hepatitis flares in hepatitis B e antigen

- (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. *J Viral Hepat.* 14(4):269-274. Apr 2007. (IF = 3.348; Citations = 7)
68. Du LY, Zhao GY, He YX, Guo Y, **Zheng BJ**, Jiang SB, Zhou YS. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. *Vaccine.* 25(15):2832-2838. April. 2007. (IF = 3.616; Citations = 17)
69. Yao X*, **Zheng BJ***, Zhou J, Xu DZ, Zhao K, Sun SH, Yuan ZH, Wen YM. Hepatitis B surface antigen-antibody complex reverted immune tolerance in chronic hepatitis B patients via modulating dendritic cells. *Vaccine.* 25(10):1771-1779. March 2007. * **Equal first-authors.** (IF = 3.616; Citations = 10)
70. Lam QL, Lo CKC, **Zheng BJ**, Ko KH, Osmond DG, Wu, Rottapel R, Lu L. Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl deficient mice. *Int Immunol.* 19(3):267-76. March 2007. (IF = 3.403; Citations = 6)
71. Zhou J, Lu LW, Zhang B, Wong S, Chen Y, Poon KW, Jiang SB, **Zheng BJ***. Genetic variations of type I interferon receptor 1 promoter and their association with chronic hepatitis B virus infection. *J Micro Infect.* 2(1):19-25. Mar. 2007. * **Corresponding author.**
72. Woo PCY, Wang M, Lau SKP, Xu HF, Poon RWS, Guo RT, Wong BHL, Gao K, Tsoi HW, Huang Y, Li KSM, Lam CSF, Chan KH, **Zheng BJ**, Yuen KY. Comparative analysis of 12 group 2c and group 2d coronavirus genomes reveals unique group and subgroup features. *J Virol.* 81(4):1574-85. February 2007. (IF = 5.150; Citations = 19)
73. Zhou J, Lu L, Yuen MF, Lam TW, Lo KK, Chung CP, Lam CL, Zhang B, Wang S, Chen Y, Wu SHW, Poon VKM, Ng F, Chan CCS, Jiang S, Yuen KY, **Zheng BJ***. Polymorphisms of interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. *J Hepatol.* 46:198-205. February 2007. * **Corresponding author.** (IF = 7.818; Citations = 9)
74. Wang M*, Di B*, Zhou DH*, **Zheng BJ***, Jing H, Lin YP, Liu YF, Wu XW, Qin PZ, Wang YL, Jian LY, Li XZ, Xu JX, Lu EJ, Li TG, Xu JG. Food markets with

- live birds as source of avian influenza. *Emerg Infect Dis*. 12 (11):1773-1775. Nov. 2006. * **Equal first-authors**. (IF = 6.794; Citations = 21)
75. Zhang SE, Xiong Q, Tang HB, Liu JY, Wu YY, Wu DP, Tian WZ, Lu JH, **Zheng BJ**, Sun J. Study on hybridized yeast-based HIV vaccine. *Chin J Microbiol Immunol*. 26(11):1033-1037. Nov. 2006.
76. Zhao XY, Lee SS, Wang KH, Chan KCW, Ng F, Chan CCS, Yam WC, Yuen KY, Ng MH, **Zheng BJ***. Functional analysis of naturally occurring mutations on open reading frame of CCR5 among HIV infected Chinese patients and the healthy controls. *Journal of Microbes and Infection*. 1(4):200-206. Oct 2006. * **Corresponding author**.
77. Du L, He Y, Wang Y, Zhang H, Ma S, Wong CKL, Wu SHW, Ng F, Huang JD, Yuen KY, Jiang S, Zhou Y, **Zheng BJ***. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits protective neutralizing antibodies: implication for developing SARS vaccines. *Virology* 353(1):6-16. Sep. 2006. * **Corresponding author**. (IF = 3.042; Citations = 18)
78. Chan CP, Siu KL, Chin KT, Yuen KY, **Zheng B**, Jin DY. Modulation of the unfolded protein response by SARS coronavirus spike protein. *J Virol*. 80(18):9279-9287. Sep. 2006. (IF = 5.150; Citations = 19)
79. Zheng Y, Cao KY, Ng SP, Daniel T.T, Chua DTT, Sham JST, Kwong DLW, Ng MH, Lu LW, **Zheng BJ***. A complementary activation of peripheral NK cell immunity in nasopharyngeal carcinoma. *Cancer Science*. 97(9):912-919. Sep. 2006. * **Corresponding author**. (IF = 3.771, Citations = 3)
80. Chan CP, Choi JW, Cao KY, Wang M, Gao Y, Zhou DH, Di B, Xu HF, Leung MF, Bergmann A, Lehmann M, Nie YM, Cautherley GW, Fuchs D, Renneberg R, **Zheng BJ***. Detection of serum neopterin for early assessment of dengue virus infection. *J infection* 53:152-158. Sep. 2006. * **Corresponding author**. (IF = 3.060; Citations = 8)
81. Lu W*, **Zheng BJ***, Xu K, Schwarz W, Du LY, Wong CKL, Chen J, Duan S, Deubel V, Sun B. Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates the virus release. *Proc Natl Acad Sci*

- USA. 103(33): 12540-12545, Aug. 2006. * **Equal first-authors.** (IF = 9.432; Citations = 28)
82. He ML*, **Zheng BJ***, Chen Y, Wong KL, Huang JD, Lin MM, Peng Y, Yuen KY, Sung JJY, Kung HF. Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. *FEBS Letters*. 580:2414-2420. May 2006. * **Equal first-authors.** (IF = 3.541; Citations = 13)
83. Yam WC, Chen JHK, Wong KH, Chan K, Cheng VCC, Lam HY, Lee SS, **Zheng BJ**, Yuen KY. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. *J Clin Virol*. 35:454-457. Apr. 2006. (IF = 3.124; Citations = 8)
84. Chan VSF, Chan KYK, Chen YX, Poon LL, Cheung ANY, **Zheng B**, Chan KH, Mak W, Ngan HYS, Xu XL, Screaton G, Tam PKH, Austyn JM, Chan LC, Yip SP, Peiris MJ, Khoo US, Lin SCL. Homozygous L-SIGN (*CLEC4M*) plays a protective role in SARS coronavirus infection. *Nat. Genet*. 38:47-53. Jan 2006. (IF = 34.284; Citations = 46)
85. Guan Y, Zhong NS, Chen H, Smith GJ, **Zheng B**. An averted SARS outbreak, In: JCK Chan, VCW Taam Wong, *Challenges of Severe Acute Respiratory Syndrome*. Singapore, Elsevier, 2006, 94-100.
86. Wang M*, Yan MY*, Xu HF*, Liang WL*, Kan B*, **Zheng B***, Chen H, Zheng H, Xu YM, Zhang EM, Wang HX, Ye JR, Li GC, Li MC, Cui ZG, Liu YF, Guo RT, Liu XN, Zhan LH, Zhou DH, Zhao AL, Hai R, Yu DZ, Guan Y, Xu JG. SARS-CoV infection in a restaurant from palm civet. *Emerg. Infect. Dis*. 11:1860-1865. Dec. 2005. * **Equal first-authors.** (IF = 6.794; Citations = 28)
87. Du L, Wang Y, Shen C, He Y, **Zheng BJ**, Zhou Y. Strong antigenicity and neutralizing antibody induced by recombinant proteins targeting the S1 region of SARS-coronavirus imply for SARS serodiagnosis and vaccine development. *Chin J Lab Technol*, 1(1):7-12. Dec. 2005.
88. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, **Zheng BJ**, Martin MC, Zhong NS, Lu PY. Using siRNA in prophylactic and therapeutic regimens

- against SARS coronavirus in Rhesus macaque. *Nat. Med.* 11:944-951. Sep. 2005. (IF = 27.136; Citations = 146)
89. Zhang M, Ko KH, Shen LJ, Fu KT, Srivastava G, **Zheng B**, Lau YL, Lu L. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. *Int. Immunol.* 17:1081-92. Aug. 2005 (IF = 3.403; Citations = 21)
90. **Zheng B**, Cao KY, Chan CPY, Choi JWY, Duan ZH, Gao Y, Wang M, Di B, Hollidt JM, Bergmann A, Lehmann M, Renneberg I, Tam JSL, Chan PKS, Cautherley GWH, Fuchs D, Renneberg R. Serum Neopterin for Early Assessment of Severity of Severe Acute Respiratory Syndrome. *Clin Immunol.* 16:18-26. Jul. 2005. (IF = 3.863; Citations = 7)
91. Duan ZP, Zhao XY, Huang DZ, He LX, Yu Chen Y, Zhao CH, **Zheng BJ***. RANTES gene single nucleotide polymorphisms and expression in chronic Hepatitis B Virus infection. *Chin Med J (Engl)*. 118:909-914. Jun. 2005. * **Corresponding author.** (IF = 0.952; Citations = 3)
92. Zhao XY, Lee SS, Wong KH, Chan KCW, Ng F, Chan CCS, Han D, Yam WC, Yuen KY, Ng MH, **Zheng BJ***. Functional analysis of naturally occurring mutations in open reading frame of CCR5 in Chinese HIV patients and healthy controls. *JAIDS*. 38:509-517. Apr. 2005. * **Corresponding author** (IF = 4.207; Citations = 2)
93. **Zheng BJ***, Guan Y, He ML, Sun HZ, Du LY, Zheng Y, Wong KL, Chen H, Chen Y, Lu L, Tanner JA, Watt RM, Niccolai N, Bernini A, Spiga O, Woo PCY, Kung HF, Yuen KY, Huang JD*. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. *Antiviral Therapy*. 10:393-403. Mar. 2005. * **Corresponding author.** (IF = 4.322; Citations = 10)
94. Tanner JA*, **Zheng BJ***, Zhou J, Watt RM, Jiang JQ, Wong KL, Lin YP, Yu Lu LY, Kesel AJ, Huang JD. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. *Chem Biol* 12:303-311. Mar. 2005 * **Equal first-authors.** (IF = 6.523; Citations = 22)

95. Qu D, **Zheng B**, Yao X, Guan Y, Yuan ZH, Zhong NS, Lu LW, Xie JP, Wen YM. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) in mice induced local and serum antibodies. *Vaccine* 23:924-931. Jan. 2005. (IF = 3.616; Citations = 26)
96. Di B, Hao W, Gao Y, Wang M, Wang YD, Qiu LW, Wen K, Zhou DH, Wu XW, Lu EJ, Liao ZY, Mei YB, **Zheng BJ**, Che XY. Monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay reveals high sensitivity of the nucleocapsid protein in acute-phase sera of severe acute respiratory syndrome patients. *Clin Diagn Lab Immunol.* 12:135-140. Jan. 2005. (IF = 2.373; Citations = 10)
97. Wang M, Gao Y, Zhou DH, Wu XW, Chen XS, Di B, Liu YF, Chen F, Du L, Xu HF, Gu J, **Zheng BJ**, Xu JG. The effects of 4 laboratory test kits in early detecting of severe acute respiratory syndrome coronavirus. *Zhonghua Liu Xing Bing Xue Za Zhi.* 26:22-24. Jan. 2005.
98. Bernini A, Spiga O, Ciutti A, Chiellini S, Bracci L, Yan XY, **Zheng B**, Huang JD, He ML, Song HD, Hao P, Zhao GP, Niccolai N. Prediction of quaternary assembly of SARS coronavirus peplomer. *Biochem Biophys Res Commun.* 325:1210-1214. Dec. 2004. (IF = 2.548; Citations = 10)
99. Zhang M, Ko KH, Lam QLK, Cherry Kam Chun Lo CKC, Xu DJL, Shen LJ, **Zheng BJ**, Srivastava G, Lu LW. Novel Function of TNF Cytokines in Regulating Bone Marrow B Cell Survival. *Cellular & Molecular Immunology.* 1:447-453. Dec. 2004. (IF = 2.765)
100. Wang M, Xu HF, Mo ZY, **Zheng BJ**, Gu J, Qin PZ, Zhang ZB, Zou XZ, Liang CY, Zhao YT, Gao K. Anti-SARS virus antibody responses against human SARS-associated coronavirus and animal SARS-associated coronavirus-like virus. *Chin Med J (Engl).* 117:1723-5. Nov. 2004. (IF = 0.952; Citations = 1)
101. Zhao XY, Lee SS, Wong KH, Chan KCW, He ZM, Ma S, Ng F, Chan CCS, Ho T, Ng MH, **Zheng BJ***. A novel CCR5 mutation selectively affects immunoreactivity and fusogenic property of the HIV co-receptor. *AIDS.* 18:1729-1732. Aug. 2004. * **Corresponding author** (IF = 4.909; Citations = 3)

102. Zhao XY, Lee SS, Wong KH, Chan KCW, Ma S, Yam WC, Yuen KY, MH, **Zheng BJ***. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. *Eur. J Immunogenet.* 31:179-183. Aug. 2004. * **Corresponding author** (IF = 1.900; Citations = 9)
103. **Zheng B**, He ML, Wong KL, Lum CT, Leo L.M. Poon LLM, Peng Y, Guan Y, Marie C.M. Lin MCM, Kung HF. Potent Inhibition of SARS-Associated Coronavirus (SCoV) Infection and Replication by Type I Interferons (IFN α/β) but not by Type II Interferon (IFN γ). *J Interferon Cytokine Res.* 24:388-390. Jul. 2004. (IF = 1.627; Citations = 21)
104. **Zheng BJ**, Guan Y, Tang QQ, Cheng D, Xie FY, He ML, Chan KW, Wong KL, Lader E, Woodle MC, Lu PY, Li BJ, Zhong NS. Prophylactic and Therapeutic Effects of Small Interfering RNA Targeting SARS-Coronavirus. *Antiviral Ther.* 9:365-374. Jun. 2004. (IF = 4.322; Citations = 38)
105. **Zheng BJ**, Zhou J, Qu D, Siu KL, Lam TW, Lo HY, Lee SS, Wen YM. Selective Functional Deficit in Dendritic Cell – T Cell Interaction Is a Crucial Mechanism in Chronic Hepatitis B Virus Infection. *J. Viral Hepat.* 11:217–224. May 2004. (IF = 3.348; Citations = 30)
106. Woo PCY, Lau SKP, Tsoi HW, Chan KH, Wong BHL, Che XY, Tam VKP, Tam SCF, VCC, Hung IFN, Wong SSY, **Zheng BJ**, Guan Y, Yuen KY. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. *Lancet.* 363: 841-45. Mar. 2004 (IF = 30.758; Citations = 57)
107. Wong ATY, Tsang OTY, Wong KH, Wong MYF, Lim WL, **Zheng BJ**, Lee SS, Lai ST, Yuen KY. Coronavirus infection in an AIDS patient. *AIDS* 18:829-830. Mar. 2004. (IF = 4.909; Citations = 2)
108. **Zheng BJ**, Guan Y, Wong KH, Zhou J, Wong KL, Young BWY, Lu LW, Lee SS. SARS-related Virus Predating SARS Outbreak, Hong Kong. *Emerg. Infect. Dis.* 10:176-178. Feb. 2004. (IF = 6.794; Citations = 38)
109. Cheng VC, Hung IF, Tang BS, Chu CM, Wong MM, Chan KH, Wu AK, Tse DM, Chan KS, **Zheng BJ**, Peiris JS, Sung JJ, Yuen KY. Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. *Clin Infect Dis* 38:467-75. Feb. 2004. (IF = 8.195; Citations = 29)

110. Guan Y, Peiris JSM, **Zheng B**, Poon LLM, Chan KH, Zeng FY, Chan CWM, Chan MN, Chen JD, Chow KYC, Hon CC, Hui KH, Li J, Li VYY, Wang Y, Leung SW, Yuen KY, Leung FC. Molecular epidemiology of the novel coronavirus that causes Severe Acute Respiratory Syndrome. *Lancet*. 363:99-104. Jan. 2004. (IF = 30.758; Citations = 47)
111. Poon LL, Chan KH, Wong OK, Cheung TK, Ng I, **Zheng BJ**, Seto WH, Yuen KY, Guan Y, Peiris JS. Detection of SARS Coronavirus in Patients with Severe Acute Respiratory Syndrome by Conventional and Real-Time Quantitative Reverse Transcription-PCR Assays. *Clin Chem*. 50:67-72. Jan. 2004. (IF = 6.263; Citations = 42)
112. He ML*, **Zheng B***, Peiris JSM, Lin MCM, Peng Y, Poon LLM, Yuen KY, Kung HF, Guan Y. Inhibition of SARS-Associated Coronavirus Infection and Replication by RNA Interference. *JAMA*. 290:2665-2666. Nov. 2003. * **Equal first-authors**. (IF = 28.899; Citations = 47)
113. Guan Y*, **Zheng BJ***, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JSM, Poon LLM. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. *Science*. 302:276-278. Oct. 2003. * **Equal first-authors**. (IF = 29.747; Citations = 519)
114. Zhong NS*, **Zheng BJ***, Li YM, Poon LLM, Xie ZH, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ, Xu J, Li DX, Yuen KY, Peiris JSM, Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. *Lancet*. 362:1353-1358. Oct. 2003. * **Equal first-authors**. (IF = 30.758; Citations = 128)
115. Zeng FY, Chan CW, Chan MN, Chen JD, Chow KY, Hon CC, Hui KH, Li J, Li VY, Wang CY, Wang PY, Guan Y, **Zheng B**, Poon LL, Chan KH, Yuen KY, Peiris JS, Leung FC. The Complete Genome Sequence of Severe Acute Respiratory Syndrome Coronavirus Strain HKU-39849 (HK-39). *Exp Biol Med* (Maywood). 228:866-873. Jul. 2003. (IF = 2.635; Citations = 36)
116. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, **Zheng BJ**, Ng WL, Lai RW, Guan Y, Yuen

- KY; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet*. 361:1767-1772. May 2003. (IF = 30.758; Citations = 623)
117. **Zheng BJ**, Zhao XY, Zhu NS, Chan CP, Wong KH, Chan KCW, Yam WC, Yuen KY, Lee SS. Polymorphism of CCR5 Gene in Southern Chinese population and the Effects on Disease Progression in HIV Patients. *AIDS* 16:2480-2482. Dec. 2002. (IF = 4.909; Citations = 5)
118. **Zheng BJ**, Ng MH, Chan KW, Tam S, Woo PCY, Ng SP, Yuen KY. A Single Dose of Oral DNA Immunization Delivered by Attenuated *Salmonella typhimurium* Down-regulates Transgene Expression in HBsAg Transgenic Mice. *Eur J Immun* 32:3294-3304. Nov. 2002. (IF = 5.179; Citations = 8)
119. **Zheng B**, Woo PC, Ng M, Tsoi H, Wong L, Yuen K. A crucial role of macrophage in the immune responses to oral vaccination against hepatitis B virus in a murine model. *Vaccine* 20:140-147. Oct. 2002. (IF = 3.616; Citations = 15)
120. **Zheng BJ**, Ng SP, Chua DTT, Sham JST, Kwong DLW, Lam CK, Ng MH. Peripheral $\gamma\delta$ T Cell Deficit in Nasopharyngeal Carcinoma. *Int J Cancer*, 99:213-217. May 2002. (IF = 4.722; Citations = 8)
121. Cheng WM, Chan KH, Chen HL, Luo RX, Ng SP, Luk W, **Zheng BJ**, Ji MF, Liang JS, Sham JST, Wang DK, Zong YS, Ng MH. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. *Int J Cancer* 97:489-492. Feb. 2002. (IF = 4.722; Citations = 20)
122. Cheng W, Chen G., Chen H, Luo R, Wu Z, Lu Y, **Zheng B**, Ji M, Liang J, Cen X, Wang D, Zong Y, Wu W. Assessment of nasopharyngeal carcinoma risk by EB virus antibody profile. *Chinese Journal of Oncology*. 24 (6):561-563. 2002.
123. Chua D, Huang J, **Zheng BJ**, Lau SY, Luk W, Kwong DLW, Sham JST, Moss D, Yuen KY, Im S, Ng MH. Adoptive transfer of autologous EBV specific cytotoxic T cells for nasopharyngeal carcinoma. *Int J Cancer* 94:73-80. Oct. 2001. (IF = 4.722; Citations = 49)
124. **Zheng BJ**, Ng MH, He LF, Yao X, Chan KW, Yuen KY, Wen YM. Therapeutic efficacy of hepatitis B surface antigen-antibody-recombinant composite in HBsAg transgenic mice. *Vaccine* 19:4219-4225. Oct. 2001. (IF = 3.616; Citations = 28)

125. **Zheng BJ**, Chan KW, Im S, Chua D, Sham JST, Tin PC, He ZM, Ng MH. Anti-tumor effect of human peripheral $\gamma\delta$ T cells in nude mouse model. *Int. J. Cancer*. 92:421-425. May 2001. (IF = 4.722; Citations = 32)
126. Woo PCY, Wong LP, **Zheng BJ**, Yuen KY. Unique immunogenicity of hepatitis B virus DNA vaccine presented by liver-attenuated Salmonella typhimurium. *Vaccine* 19:2945-2954. Apr. 2001. (IF = 3.616; Citations = 46)
127. **Zheng B**, Lam C, Im S, Huang J, Luk W, Lau SY, Yau KS, Wong CK, Yao K, Ng MH. Distinct tumor specificity and IL-7 requirements of CD56⁻ and CD56⁺ subsets of human $\gamma\delta$ T cells. *Scan J Immunol*. 53:40-48. Jan. 2001. (IF = 2.108; Citations = 4)
128. **Zheng BJ**, Graham FL, Prevec L. Transcription units of E1a, E1b and pIX region of bovine adenovirus type 3. *J. Gen. Virol*. 80: 1735-1742. 1999. (IF = 3.260; Citations = 6)
129. **Zheng BJ**, Mittal SM, Graham FL, Prevec L. The E1 sequence of bovine adenovirus type 3 and complementation of human adenovirus type 5 E1A function in bovine cells. *Virus Res*. 31:163-168. 1994. (IF = 2.563; Citations = 24)
130. **Zheng BJ**, Graham FL, Johnson DC, Hank T, McDermott MR, Prevec L. Immunogenicity of tandem repeats of a linear neutralizing epitope of the herpes simplex gD protein when expressed in recombinant adenovirus vectors. *Vaccine* 11:1191-1198. 1993. (IF = 3.616; Citations = 27)
131. **Zheng BJ**, Ma GZ, Tam JS, Lo SK, Ng MH, Lam BC, Yeung CY, Lo M. The Effects of Maternal Antibodies on Neonatal Rotavirus Infection. *Pedia. Infect. Dis. J.* 10:865-868. 1991. (IF = 2.854; Citations = 4)
132. **Zheng BJ**, Chang RX, Ma GZ, Xie JM, Liu Q, Liang XR, Ng MH. Rotavirus Infection of the Oropharynx and Respiratory Tract in Young Children. *J. Med. Virol*. 34:29-37. 1991. (IF = 2.470; Citations = 25)
133. Tam JS, **Zheng BJ**, Lo SK, Yeung CY, Lo M, Ng MH. Distinct Populations of Rotavirus Circulating Neonates and Older Infants. *J. Clin. Microbiol*. 28:1033-1038. 1990. (IF = 4.162; Citations = 16)

134. **Zheng BJ**, Lo SK, Tam JS, Lo M, Yeung CY, Ng MH. Prospective Study of Community Acquired Rotavirus Infection. *J. Clin. Microbiol.* 27:2083-2090. 1989. (IF = 4.162; Citations = 26)
135. **Zheng BJ**, Lam WP, Yan YK, Lo SK, Lung ML, Ng MH. Direct Identification of Serotypes of Natural Human Rotavirus Isolates by Hybridization Using cDNA Probes Derived from Segment 9 of the Rotavirus Genome. *J. Clin. Microbiol.* 27:552-557. 1989. (IF = 4.162; Citations = 23)
136. **Zheng BJ**, et al. A Study of IgG, IgM, IgA Specific Antibodies in Acute- and Convalescent- Sera of Infants with Human Rotavirus Infection. *Chinese J Immuno.* 5:32-33. 1989.
137. **Zheng BJ**, Han SX, Yan YK, Liang XR, Ma GZ, Yang Y, Ng MH. The Development of Neutralizing Antibodies and Group A Common Antibodies against Natural Infection with Human Rotavirus. *J. Clin. Microbiol.* 26:1506-1512. 1988. (IF = 4.162; Citations = 23)
138. Tam JS, **Zheng BJ**, Yan YK, Lo SK, Yeung CY, Lo M, Ng MH. Occurrence of Rotaviruses in Guangzhou and Hong Kong. *J. Infect. Dis.* 157:357-363 1988. (IF = 5.865; Citations = 5)
139. **Zheng BJ**, et al. Serological Study of Human Rotavirus Infection in Population before and after Autumn Diarrhea in Guangzhou. *Chinese J Immuno.* 4:310. 1988.
140. Liang XR, Ma GZ, **Zheng BJ**, Mo EM, Li DH, Zhuo MY. Inhibitory Effect of Interferon on Rotavirus. *Journal of Interferon Research* 7(6):794. 1987.
141. **Zheng BJ**, et al. Analysis of Genomic RNA of Human Rotavirus by Polyacrylamide Gel Electrophoresis in Guangzhou. *Acad. J. Sun Yat Sen Univ. Med. Sci.* 7:1-14. 1986.
142. Zhang MG and **Zheng BJ**. Comparative Study of Several Laboratory Diagnostic Methods of Human Rotavirus Infection. *Acad. Med. Guangzhou* 13:63-65. 1985.
143. Liang XR, **Zheng BJ**, et al. Inhibitory Effect of Interferon on Rotavirus. *Guang Dong Med. J.* 6:2-4. 1985.

Journal papers submitted

1. Zhao X, Zhang H, Wong KH, Chan KC, Sui HY, Chen D, Poon V, Jiang S, Li N, Lee SS, Xu HF, **Zheng BJ***. novel mutation in CXCL12 α 3'UTR: identification, characterization, and functional impact on mRNA splicing and HIV-1 infection. Submitted to *AIDS*. * **Corresponding author**.
2. Wang M, Lin YP, Luo SW, Xu HF, Sui HY, Zheng Y, Du LY, Wong KL, Lui XN, Guo RT, Zhou DH, Che XY, Xu JG, Huang JD, **Zheng BJ***. Identification and Characterization of SARS Coronavirus-like Virus in Rats Surrounding Markets in Guangzhou, China. Submitted to *Emerg Infect Dis*. * **Corresponding author**. (IF = 5.094)
3. Chen Y, Ling TY, Chan VSF, To LYF, **Zheng BJ**, Huang FP, Cheng MC, Lee SH, Khoo US, Yu J, Lin CLS. A subset of putative lung stem/progenitor cells are the major target for avian influenza H5N1 virus infection in human lung. Submitted to *New Engl J Med*. (IF = 52.589)
4. Chung NPY, Chen YX, Hwang HL, Chan VSF, Chang KP, Lee CH, Xu X, Gao GF, **Zheng B**, Austyn JM, Lin CLS. Binding of HIV-1 gp120 to DC-SIGN primes dendritic cells for killing by multiple stimuli. Submitted to *Science*. 2010.

Invited oral presentations in international and national conferences:

1. “Turn residue at the helix clamp motif of reverse transcriptase is crucial for replication for both hepatitis B virus and human immunodeficiency virus” in 2007 International Meeting on the Molecular Biology of Hepatitis B Viruses” 16-20 September, 2007. Rome, Italy.
2. “HBsAg-HBIg complex modulates antigen presentation of dendritic cells from chronic hepatitis B patients” in 12th International Symposium on Viral Hepatitis and Liver Diseases. 1-5 July, 2006. Paris, France
3. “Animal source of SARS” in the 4th national conference for Microbiology and Immunology. 14-16 September, 2004. Chongqing, China.
4. “Effects of single nucleotide polymorphism in the RANTES promoter region on HIV infection and disease progression in indigenous Chinese” in XV international AIDS conference. 11-16 July, 2004. Bangkok, Thailand.

5. “SARS – from animals to man: New Viral Threats to Human Health Worldwide” in Gaslini International Committed to the Protection and Enhancement of Children’s Health. 21 June - 2 July, 2004. Genova, Italy.
6. “SARS – from animals to man: New Viral Threats to Human Health Worldwide” in 12° CONGRESSO NAZIONALE della SOCIETÀ di MICROBIOLOGIA MEDICA ODONTOIATRICA e CLINICA. 20-22 July, 2004. Genova, Italy.
7. “The Study of Oral DNA Vaccine for Immune Therapy of Chronic Hepatitis B Virus Infection” in New Ideas and Developments in Antimicrobial Vaccines. 16-18 October, 2003, Shanghai, China.
8. “The Role of $\gamma\delta$ T Cells Plays in Immune Surveillance against Nasopharyngeal Carcinoma” in 7th World Congress on Advances in Oncology and the 5th International Symposium on Molecular Medicine, 10-12 October, 2002, Crete, Greece.
9. “HBV Oral DNA Vaccine” in the 4th National conference on Medical-Molecular Microbiology and Immunology, 18-21 September, 2001, Urumqi City, China.
10. “The E1a, E1b and Pix Regions of Bovine Adenovirus Type 3 Function as Nested Overlapping Transcription Units” in Advances in Molecular Virology – International Conference on Medical Virology, 19-22 October, 1998, Beijing China.

Poster presentation in international and national conferences: (Since 2002)

1. Lin YP, Shum KT, Tanner JA, **Zheng BJ**. Study of DNA aptamers binding H5N1 virus nucleoprotein. Thailand Conference on Emerging Infectious and Neglected Diseases. Jun 3-4, 2010. Chonburi, Thailand.
2. Chen DQ, **Zheng BJ**. Association of candidate susceptible loci with chronic hepatitis B virus infection in Chinese population. European Congress of Clinical Microbiology and Infectious Diseases. Apr. 10-13 2010. Vienna, Austria.
3. Yang L, **Zheng BJ**. Establishment of a non-transgenic mouse model for chronic hepatitis B virus infection. European Congress of Clinical Microbiology and Infectious Diseases. Apr. 10-13 2010. Vienna, Austria.
4. Zhang G, Chen M, **Zheng BJ**. Development of recombinant Adeno-associated virus vector delivering short-hairpin RNAs to inhibit the replication of influenza.

- European Congress of Clinical Microbiology and Infectious Diseases. Apr. 10-13 2010. Vienna, Austria.
5. Lin YP, Tanner JA, **Zheng BJ**. In vivo selection and characterization of DNA aptamers against H5N1 virus nucleoprotein. European Congress of Clinical Microbiology and Infectious Diseases. Apr. 10-13 2010. Vienna, Austria.
 6. **Zheng BJ**, Yao X, Zhou J, Wen YM. HBsAg-HBIg complex modulates antigen presentation of dendritic cells from chronic hepatitis B patients. HEP DART 2009 Frontiers in Drug Development for Viral Hepatitis. Dec. 6-10. 2009. The Big Island, Hawaii, USA
 7. Zeng Y, Chan KCW, Chan CS, Ng F, Wong KH, **Zheng BJ**. Detection of HIV specific cytotoxic T lymphocytes viral delivery system. The 19th European Congress of Clinical Microbiology and Infectious Diseases. May 16-19, 2009. Helsinki, Finland.
 8. Zeng Y, Zhou J, Chen DQ, Poon CKM, Ng F, Yuen KY, **Zheng BJ**. A SNP in IFNGR1 promoter is correlated to the susceptibility to chronic HBV infection in Chinese population. The 19th European Congress of Clinical Microbiology and Infectious Diseases. May 16-19, 2009. Helsinki, Finland.
 9. **Zheng BJ**, Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Jin DY, Zhou Y, Yuen KY. SARS-CoV S Protein Induces Strong Mucosal Immune Responses and Provides Long-term Protection Against SARS-CoV Infection. Vaccine 2nd Congress. December 7-9, 2008. Boston, MA, USA.
 10. **Zheng BJ**, Zhou J, Huang JD, Lu L, Yuen KY. An IFN- α/β receptor 1 promoter variant and hepatitis B virus synergistically increase the susceptibility to chronic hepatitis B. 2008 International Meeting: The Molecular Biology of Hepatitis B Viruses. August 17-21, 2008, San Diego, California, USA.
 11. **Zheng BJ**, Zhao XY, Lee SS, Wong KH, Chan KCW, Ng F, Yam WC, Yuen KY. Study of Polymorphisms in HIV-1 Co-receptors and Their Ligands in Chinese Population and Their Effects on HIV-1 Infection. XVII International AIDS Conference, 3-8 August 2008, Mexico City, Mexico.
 12. Zhang HJ, Wang YX, Wu H, Zhang QW, Wen YM, **Zheng BJ**. Mutations of the turn between helix H and I of HIV-1 reverse transcriptase affect RT incorporation

- into viral particles and subsequent viral replication. 25 years of HIV. May 19-21, 2008, Paris, France.
13. **Zheng BJ**, Yao X, Zhou J, Wen YM. HBsAg-HBIg complex modulates antigen presentation of dendritic cells from chronic hepatitis B patients. Hep DART 2007: frontiers in drug development for viral hepatitis. December 9-13, 2007, Lahaina, Hawaii, USA.
 14. **Zheng BJ**, Zhao XY, Lee SS, Wong KH, Chan KCW, Ng F, Chan CCS, Yam WC, Yuen KY, Ng MH. Polymorphisms of HIV-1 Co-receptors and Their Ligands in Chinese Population and the Effects on HIV-1 Infection and the Disease Progression. Keystone Symposia: Molecular and Cellular Determinants of HIV Pathogenesis (X8). March 25 - 30, 2007, Whistler Resort, Whistler, British Columbia, Canada.
 15. **Zheng BJ**, Lee SS, Wong KH, Chan KCW, Chan CCS, Ng F, Huang FP, Yuen KY. A feasibility study for detection of HIV specific cytotoxic T lymphocytes using rAAV delivery system. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 22–25 July 2007, Sydney, Australia.
 16. **Zheng BJ**, Zhao XY, Lee SS, Wong KH, Chan KCW, Ng F, Chan CCS, Yam WC, Yuen KY, Ng MH. Polymorphisms of HIV-1 Co-receptors and Their Ligands in Chinese Population and the Effects on HIV-1 Infection and the Disease Progression. 1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity. 10-13 June 2007 Budapest, Hungary.
 17. Zhou J, Huang JD, Poon VKM, Chen DQ, Chan CCS, Ng F, Guan XY, Watt RM, Lu L, Yuen KY, **Zheng BJ**. A mechanism underlying susceptibility to HBV infection: HBV down-regulate transferase-1 type I interferon receptor 1 via suppressing poly(ADP-ribose) 2007 International Meeting: The Molecular Biology of Hepatitis B Viruses. September 16-20, 2007. Rome, Italy.
 18. Sui HY, Wong CKL, Huang JD, **Zheng BJ**. Long term expression of small interfering RNA targeting M2 gene induces effective inhibition of influenza A virus replication. Options for the Control of Influenza VI Conference. June 17-23 2007. Toronto, Ontario, Canada.
 19. Lin YP, Wang M, Di B, Zhou DH, Jing HQ, Liu YF, Wu XW, Qin FZ, Wang YL, Jian LY, Li XZ, Lu EJ, Li TG, Xu JG, **Zheng BJ**. Food markets with live birds as

- source of avian influenza. Options for the Control of Influenza VI Conference. June 17-23 2007. Toronto, Ontario, Canada.
20. **Zheng BJ**, Zhao XY, Lee SS, Wong KH, Chan KCW, Ng F, Chan CCS, Yam WC, Yuen KY, Ng MH. Mutational Analysis of HIV-1 Co-receptors and Their Ligands in Chinese Population. 18th Annual ASHM Conference. 11-14 October, 2006. Melbourne, Australia.
 21. Zhou J, Lu LW, Poon KM, Wu HW, Ng F, Chan SC, Wen YM, **Zheng BJ**. Polymorphisms in the type I interferon receptor I promoter affect its transcriptional activity and susceptibility to chronic HBV infection. The 2006 International Meeting: The Molecular Biology of Hepatitis B Viruses. 17-20 September, 2006. Vancouver, Canada.
 22. **Zheng BJ**, Zhou J, Wu HW, Poon KM, Ng F, Chan CS, Lu LW, Wen YM. IFNAR1 promoter polymorphisms associated with susceptibility to chronic HBV infection and functional implication. The 2006 International Meeting: The Molecular Biology of Hepatitis B Viruses. 17-20 September, 2006. Vancouver, Canada.
 23. Zhou J, Wu SHW, Poon VKM, Ng F, Chan CCC, Qu D, Wen YM, Lu LW, **Zheng BJ**. Interferon receptor 1 promoter polymorphisms and susceptibility to chronic hepatitis B virus infection. 12th International Symposium on Viral Hepatitis and Liver Diseases. 1-5 July, 2006. Paris, France.
 24. Du L, Zhou Y, He Y, Ma S, Yuen KY, Jiang S, **Zheng BJ**. Intranasal vaccination with adeno-associated virus encoding the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein induces strong and prolonged systemic and local antibodies with neutralizing activity. The American Society for Virology 25th Annual Meeting (25th ASV). 15-19 July, 2006. Madison, Wisconsin, USA.
 25. Du L, Zhou Y, He Y, Ma S, Yuen KY, Jiang S, **Zheng BJ**. Vaccination with adeno-associated virus vector encoding severe acute respiratory syndrome coronavirus S protein induces potent and prolonged antibodies. 16th European Congress of Clinical Microbiology and Infectious Diseases (16th ECCMID). 1-4 April 2006. Nice, France.

26. **Zheng BJ**, Lee SS, Wong KH, Chan KCW, Chan CS, Ng F, Huang FP, Yuen KY. Development of New Technique for Detection of HIV Specific Cytotoxic T Lymphocytes. Keystone Symposia HIV Vaccines (×6). 27 March-2 April, 2006. Keystone, Colorado, USA.
27. **Zheng BJ**, Lee SS, Wong KH, Chan KCW, Zhang HJ, Wu SHW, Lu LW. Ex vivo expansion of functional CD4 T cells from HIV patients. The 6th International Workshop on HIV, Cells of Macrophage/Dendritic Lineage and Other Reservoirs. 5-7 October 2005. Varenna, Italy.
28. **Zheng BJ**, Duan ZP, Zhao XY, Huang DZ, He LX, Chen Y, Zhao CH. RANTES gene single nucleotide polymorphisms and expression in patients with chronic hepatitis B virus infection. International Meeting on the Molecular Biology of Hepatitis B Viruses. 18-21 September 2005. Heidelberg, Germany.
29. Cao KY, Zheng Y, Ng SP, Chua DTT, Sham JST, Kwong DLW, Ng MH, **Zheng BJ**. Peripheral NK Cells Play a Complementary Role for Anti-tumor Immunity in Nasopharyngeal Carcinoma Patients. Keystone Symposia – Basic Aspects of Tumor Immunology II (C3). 19-24 March, 2005. Keystone, Colorado, USA.
30. Zhao XY, Lee SS, KH Wong KH, Chan KCW, Ng F, Chan CCS, Yam WC, KY Yuen KY, Ng MH, **Zheng BJ**. Polymorphisms and Functional Analysis of CCR5 Gene in Southern Chinese HIV Patients and Healthy Controls. Keystone Symposia – HIV Pathogenesis (X7). 9-15 April, 2005. Banff, Alberta, Canada.
31. Zhao XY, Lee SS, Wong KH, Chan KCW, Ma S, Chan CS, **Zheng BJ**. A Novel CCR5 Mutation Selectively Affects Immunoreactivity and Fusogenic Property of the HIV Co-receptor in a Slow Progressing HIV Patient. 13th International Symposium on HIV & Emerging Infectious Diseases. 3-5 June, 2004. Toulon, France.
32. **Zheng BJ**, Guan Y, Tang QQ, Cheng D, Xie FY, He ML, Chan KW, Wong KL, Lader E, Woodle MC, Lu PY, Li BJ, Zhong NS. Prophylactic and Therapeutic Effects of Small Interfering RNA Targeting SARS-Coronavirus. International Conference on SARS – one year after the (first) outbreak. 8-11 May, 2004. Lubeck, Germany.

33. Poon LLM, Chan KH, Nicholls J.M, **Zheng B**, Yuen KY, Guan Y, Peiris JSM. Characterization of a novel coronavirus responsible for severe acute respiratory syndrome. *Options for the Control of Influenza V*, 2004, 805-808.
34. Sun H, Huang J, **Zheng B**. Bismuth as an enzyme inhibitor: from antibacterium to antiviral. *The 8th International Symposium on Applied Bioinorganic Chemistry*, April 2-5, 2004.
35. He ML, **Zheng B**, Guan Y, Chen Y, Wong KL, Huang J, Peng Y, Yuen KY and Kung H. The inhibitory effects of siRNAs targeting the replicase or structural genes of the SARS-associated coronavirus (SARS-CoV) on viral replication. *10th SCBA International Symposium*. 18-23 July 2004. Beijing, China.
36. Chan CP, Siu KL, **Zheng B** and Jin D. Subcellular localization of SARS coronavirus orf8 protein. *10th SCBA International Symposium*, 18-23 July 2004. Beijing, China.
37. Zhao XY, Ng MH, Wong KH, Chan KCW, Lee SS, **Zheng BJ**. Effects of single nucleotide polymorphism in the RANTES promoter on HIV infection in indigenous Chinese. *The 42nd National Scientific Conference of Australia*, November 2003. South Australia. Australia.
38. **Zheng BJ**, Yuen KY, Lee SS, Qu D, Ng SP, Leung SK, Ng MH, Wen YM. Selective Functional Deficit of Dendritic Cells is Crucial in the Mechanism of Chronic Hepatitis B Virus Infection. *11th international Symposium on Viral Hepatitis & Liver Disease*. 6-10 April, 2003. Sydney, Australia.
39. Lee SS, K Wong KH, Chan KCW, Zhu NS, Chan SCP, **Zheng BJ**. A Predominant Mutation of CCR5 Gene and Its Effect on HIV Disease Progression in Chinese Patients. *XIV International AIDS Conference*. 7 –12 July, 2002. Barcelona, Spain.
40. **Zheng BJ**, Leung SK, Wong KH, Chan KCW, Lee. Expression of CCR5 on Dendritic Cells Is a Surrogate Marker for HIV Disease Progression. *9th Conference on Retroviruses and Opportunistic Infections*, 24-28 February, 2002. Seattle, USA.
41. **Zheng BJ**, Ng SP, Chua D, Sham JST, Kwong D, Lam CK, Ng MH. Quantitative and Qualitative Deficits of Peripheral $\gamma\delta$ T Cells in Patients with Active Nasopharyngeal Carcinoma” in *6th international Symposium on Predictive Oncology & Intervention Strategies*, 9-12 February, 2002. Paris, France.

Patents

1. Oral DNA Composition for HBV Chronic Infection. Chinese Patent No. ZL 03110738.9, issued on 19 August 2009. Inventors: Ng MH, Yuen KY, **Zheng BJ**.
2. Synthetic Peptide Targeting Critical Sites on the SARS-Associated Coronaviurs Spike Protein Responsible for Viral Infection and a Method of Use Thereof. U.S. Patent No. 7,491,489, issued on 17 February 2009. Inventors: **Zheng BJ**, Guan Y, Huang JD, He ML.
3. Inhibition of SARS-Associated Coronavirus (SCoV) Infection and Replication by RNA Interference. U.S. Patent No. 7,429,656, issued on 30 September 2008. Inventors: Kung HF, He ML, **Zheng BJ**, Guan Y, Lin MCM, Peng Y.
4. Isolation and Characterization of the Precursor Virus of Human SARS Virus: SARS-Associated Coronavirus-like Virus. U.S. Patent No. 7,361,747, issued on 22 April 2008. Inventors: Guan Y, **Zheng BJ**.
5. siRNA compositions and methods for potently inhibiting viral infection. U.S. Patent No. 61/121,614. 2009. Inventors: **Zheng BJ**, Sui H, Lin Y.
6. Combination therapy for the treatment of influenza. U.S. Patent No. 61/055,573. 2008. PCT/CN2009/000493 May 2009. Inventors: **Zheng BJ**, Yuen KY.
7. New severed acquired respiratory syndrome (SARS) coronavirus medicine target, where the medicine target is a protein encoded by an ORF3a virus gene, and has the characteristic of an ion channel, useful for manufacturing a medicament. CN101085811-A. 2006. Inventors: Sun B, **Zheng B**, Lv W, Xu K.
8. New SARS coronavirus peptide antigen has immunogenicity suitable for preparing antibody, useful for detecting SARS coronavirus antibody. CN101085812-A. 2006. Inventors: Sun B, **Zheng B**, Lv W, Xu K.
9. New interfering RNA of the SARS coronaviruses, useful for preparing a composition for treating or preventing SARS virus. CN101085986-A. 2006. Inventors: Sun B, **Zheng B**, Lv W, Xu K.
10. New isolated polynucleotide having specific length of nucleotides and comprising first nucleotide sequence useful in the manufacture of composition to treat infection

- due to respiratory virus. Patent No.: WO2006121464-A2; EP1817416-A2. 2004. Inventors: Tang Q, Lu PY, Xie FY, Woodle MC, **Zheng B**.
11. Oral DNA Composition for HBV Chronic Infection. Hong Kong Standard Patent No. 04100585.7. 2004. Inventors: Ng MH, **Zheng BJ**, Yuen KY.
 12. An Intranasal Immune Composition for SARS Virus Infection. Patent No. CN03116941.4. CN1502367-A 2003. Inventors: Zhong NS, Guan Y, **Zheng BJ**, Wen YM.
 13. New oral DNA composition comprising an attenuated strain of bacteria, useful for inducing a cell-mediated immune response in a chronically infected hepatitis B virus carrier and for suppressing transgene expression. Patent No. US2003162741-A1. WO2003072012-A2; CA2380471-A1; CN1444996-A; AU2003210122-A1; AU2003210122-A8. 2003. Inventors: Ng MH, Yuen KY, **Zheng BJ**.
 14. New recombinant adenovirus useful against rabies virus and other rhabdovirus infections comprises E1 region containing functional deletion and E3 region incorporating expression cassette coding foreign gene Canadian patent No. CA2234201. 1998. Inventors: **Zheng BJ**. Prevec L, Graham FL.

Teaching experience:

1. MBBS old curriculum
 - I. Teaching lectures and practical tutorials to second and third year MBBS students in basic and clinical microbiology
 - II. Internal examiner for MBBS II and MBBS III examinations
2. MBBS new curriculum
 - I. Teaching first and second year MBBS students in problem-based learning (PBL) program
 - II. Teaching practical tutorials to first and second year MBBS students in basic and clinical microbiology as well as infectious diseases
 - III. Developed the computer-assisted self-learning system for first and second year MBBS students
 - IV. Internal examiner of summative assessments for first and second year MBBS students

3. B. Nursing
 - I. Lectures for full-time and part-time B. Nursing students
 - II. Practical and tutorials for full-time B. Nursing students
 - III. Internal examiner for full-time and part-time B. Nursing students
4. B. Dental
 - I Teaching of first and second year B. Dental students in the form of lectures, practical and PBL
 - II. Internal examiner for second year B. Dental students
5. Principle supervisor of post-graduate students
 - I. Currently supervising 7 Ph.D and 1 M.Phil students
 - II. Five Ph.D and 3 M.Phil students have successfully graduated.

Membership in professional organizations

- 1998- Member, The Hong Kong Society of Microbiology and Infection.
1999- Member, The Hong Kong Society of Immunology.
2001- Member, Chinese Society for Microbiology and Immunology.
2002- Member, International AIDS Society (IAS).